{"url_path":"/sec/traw/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-061779-index.html","accession_number":"0001104659-26-061779","cik":"0001130598","ticker":"TRAW","issuer_name":"Traws Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-061779-index.html","primary_entity_key":"0001130598","primary_entity_name":"Traws Pharma, Inc."},"word_count":78,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\nDuring the three months ended March 31, 2026, none of our directors or officers informed us of any adoption, modification, or termination of any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).\n\n​\n\n​\n\n34\n\n[Table of Contents](#TOC)"}